{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:21:04Z","timestamp":1773325264865,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T00:00:00Z","timestamp":1403222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/eye.2014.138","type":"journal-article","created":{"date-parts":[[2014,6,20]],"date-time":"2014-06-20T09:39:14Z","timestamp":1403257154000},"page":"1100-1106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Long-term efficacy of infliximab on background vascular leakage in patients with Beh\u00e7et\u2019s disease"],"prefix":"10.1038","volume":"28","author":[{"given":"H","family":"Keino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A A","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Taki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,20]]},"reference":[{"key":"BFeye2014138_CR1","first-page":"pp 663","volume-title":"Ocular Infection and Immunity","author":"M Mochizuki","year":"1996","unstructured":"Mochizuki M, Akduman L, Nussenblatt RB . Behcet's disease. In: Pepose JS, Holland GN, Wilhelmus KR, (eds). Ocular Infection and Immunity. Mosby: St Louis, MO, USA, 1996; pp 663\u2013675."},{"key":"BFeye2014138_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/08830189709116845","volume":"14","author":"RB Nussenblatt","year":"1997","unstructured":"Nussenblatt RB . Uveitis in Behcet's disease. Int Rev Immunol 1997; 14: 67\u201379.","journal-title":"Int Rev Immunol"},{"key":"BFeye2014138_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00004397-200604620-00017","volume":"46","author":"PA Yates","year":"2006","unstructured":"Yates PA, Michelson JB . Behcet's disease. Int Ophthalmol Clin 2006; 46: 209\u2013233.","journal-title":"Int Ophthalmol Clin"},{"key":"BFeye2014138_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","volume":"50","author":"C Evereklioglu","year":"2005","unstructured":"Evereklioglu C . Current concepts in the etiology and treatment of Behcet's disease. Surv Ophthalmol 2005; 50: 297\u2013350.","journal-title":"Surv Ophthalmol"},{"key":"BFeye2014138_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00417-009-1234-z","volume":"248","author":"T Kaburaki","year":"2010","unstructured":"Kaburaki T, Araki F, Takamoto M, Okinaga K, Yoshida A, Numaga J et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Beh\u00e7et\u2019s disease. Graefes Arch Clin Exp Ophthalmol 2010; 248: 709\u2013714.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye2014138_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0039-6257(97)00026-X","volume":"42","author":"RK George","year":"1997","unstructured":"George RK, Chan CC, Whitcup SM, Nussenblatt RB . Ocular immunopathology of Beh\u00e7et\u2019s disease. Surv Ophthalmol 1997; 42: 157\u2013162.","journal-title":"Surv Ophthalmol"},{"key":"BFeye2014138_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/BF02169409","volume":"227","author":"LS Atmaca","year":"1989","unstructured":"Atmaca LS . Fundus changes associated with Behcet's disease. Graefes Arch Clin Exp Ophthalmol 1989; 227: 340\u2013344.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye2014138_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1097\/01.icu.0000247411.59213.bb","volume":"17","author":"AA Okada","year":"2006","unstructured":"Okada AA . Behcet's disease: general concepts and recent advances. Curr Opin Ophthalmol 2006; 17: 551\u2013556.","journal-title":"Curr Opin Ophthalmol"},{"key":"BFeye2014138_CR9","first-page":"1362","volume":"31","author":"S Ohno","year":"2004","unstructured":"Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004; 31: 1362\u20131368.","journal-title":"J Rheumatol"},{"key":"BFeye2014138_CR10","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease. Arthritis Rheum 2005; 52: 2478\u20132484.","journal-title":"Arthritis Rheum"},{"key":"BFeye2014138_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Y Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. . Comparison of infliximab versus ciclosporine during the initial 6-month treatment period in Behcet\u2019s disease. Br J Ophthalmol 2010; 94: 284\u2013288.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2014138_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/bjo.2009.168856","volume":"95","author":"Y Yamada","year":"2011","unstructured":"Yamada Y, Sugita S, Tanaka H, kamoi K, Takase H, Mochizuki M . Timing of recurrent uveitis in patients with Beh\u00e7et\u2019s disease receiving infliximab treatment. Br J Ophthalmol 2011; 95: 205\u2013208.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2014138_CR13","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archophthalmol.2011.2698","volume":"130","author":"AA Okada","year":"2012","unstructured":"Okada AA, Goto H, Ohno S, Mochizuki M . Multicenter study of infliximab for refractory uveoretinitis in Behcet's disease. Arch Ophthalmol 2012; 130: 592\u2013598.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2014138_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/bjo.2010.194464","volume":"95","author":"H Keino","year":"2011","unstructured":"Keino H, Okada AA, Watanabe T, Taki W . Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Beh\u00e7et\u2019s disease on infliximab therapy. Br J Ophthalmol 2011; 95: 1245\u20131250.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2014138_CR15","first-page":"pp 16","volume-title":"Report of Behcet\u2019s Disease Research Committee","author":"Y Mizushima","year":"1987","unstructured":"Mizushima Y . The Revised Criteria and Manual of Treatments of Behcet\u2019s disease. In: Report of Behcet\u2019s Disease Research Committee. Ministry of Health and Welfare of Japan: Tokyo, Japan, 1987; pp 16\u201317."},{"key":"BFeye2014138_CR16","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552\u20131563.","journal-title":"Arthritis Rheum"},{"key":"BFeye2014138_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G, D Haens G, Carbonez A et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med 2003; 348: 601\u2013608.","journal-title":"N Engl J Med"},{"key":"BFeye2014138_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, The Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509\u2013516.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2014138_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","volume":"26","author":"AM Abu El-Asrar","year":"2005","unstructured":"Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A . Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et's disease. Int Ophthalmol 2005; 26: 83\u201392.","journal-title":"Int Ophthalmol"},{"key":"BFeye2014138_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","volume":"46","author":"L Niccoli","year":"2007","unstructured":"Niccoli L, Nannini C, Benucci M, Chindamo D, Cassar\u00e0 E, Salvarani C et al. Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et\u2019s disease: a 24-month follow-up study. Rheumatology 2007; 46: 1161\u20131164.","journal-title":"Rheumatology"},{"key":"BFeye2014138_CR21","first-page":"S58","volume":"29","author":"T Handa","year":"2011","unstructured":"Handa T, Tsunekawa H, Yoneda M, Watanabe D, Mukai T, Yamamura M et al. Long-term remission of ocular and extraocular manifestations in Beh\u00e7et's disease using infliximab. Clin Exp Rheumatol 2011; 29: S58\u2013S63.","journal-title":"Clin Exp Rheumatol"},{"key":"BFeye2014138_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/rheumatology\/keq366","volume":"50","author":"N Markomichelakis","year":"2011","unstructured":"Markomichelakis N, Delicha E, Masselos S, Fragiadaki J, Kaklamanis P, Sfikakis PP . A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Beh\u00e7et's disease: a comparative 4-week study. Rheumatology 2011; 50: 593\u2013597.","journal-title":"Rheumatology"},{"key":"BFeye2014138_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s10384-010-0859-0","volume":"54","author":"T Ito","year":"2010","unstructured":"Ito T, Sonoda KH, Hijioka K, Fujimoto T, Ishibashi T . Acquired resistance to infliximab against uveitis due to Beh\u00e7et\u2019s disease after one year of administration. Jpn J Ophthalmol 2010; 54: 502\u2013504.","journal-title":"Jpn J Ophthalmol"},{"key":"BFeye2014138_CR24","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","volume":"46","author":"M Svenson","year":"2007","unstructured":"Svenson M, Geborek P, Saxne T, Bendtzen K . Monitoring patients treated with anti-TNF-\u03b1 biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 2007; 46: 1828\u20131834.","journal-title":"Rheumatology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2014138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2014138","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2014138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:21:58Z","timestamp":1684430518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2014138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,20]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFeye2014138"],"URL":"https:\/\/doi.org\/10.1038\/eye.2014.138","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,20]]},"assertion":[{"value":"22 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was supported by restricted research funds from Mitsubishi Tanabe Pharma for the Department of Ophthalmology, Kyorin University School of Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}